| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10594051 | Bioorganic & Medicinal Chemistry Letters | 2011 | 6 Pages |
Abstract
SAR development of palm site inhibitors of HCV NS5B polymerase exemplified by initial indole lead I is described. Structure-based drug design led to the incorporation of novel heterocyclic moieties at the indole C3-position which formed a bidentate interaction with the protein backbone. Further SAR development resulted in novel NS5B polymerase inhibitors exemplified by 7r with improved enzyme and replicon activity.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Gopinadhan N. Anilkumar, Charles A. Lesburg, Oleg Selyutin, Stuart B. Rosenblum, Qingbei Zeng, Yueheng Jiang, Tin-Yau Chan, Haiyan Pu, Henry Vaccaro, Li Wang, Frank Bennett, Kevin X. Chen, Jose Duca, Stephen Gavalas, Yuhua Huang, Patrick Pinto,